Compare · PCG vs VIVO
PCG vs VIVO
Side-by-side comparison of Pacific Gas & Electric Co. (PCG) and VivoPower PLC (VIVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PCG and VIVO operate in Power Generation (Utilities), so they compete in similar markets.
- PCG is the larger of the two at $39.72B, about 305.0x VIVO ($130.2M).
- PCG has been more active in the news (11 items in the past 4 weeks vs 3 for VIVO).
- PCG has more recent analyst coverage (25 ratings vs 3 for VIVO).
Pacific Gas & Electric Co.
PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, engages in the sale and delivery of electricity and natural gas to customers in northern and central California, the United States. It generates electricity using nuclear, hydroelectric, fossil fuel-fired, fuel cell, and photovoltaic sources. As of December 31, 2020, the company owns and operates approximately 18,000 circuit miles of interconnected transmission lines, 35 electric transmission substations, approximately 108,000 circuit miles of distribution lines, 68 transmission switching substations, and 758 distribution substations; and natural gas transmission, storage, and distribution system consisting of approximately 43,500 miles of distribution pipelines, approximately 6,300 miles of backbone and local transmission pipelines, and various storage facilities. It serves residential, commercial, industrial, and agricultural customers, as well as natural gas-fired electric generation facilities. The company was founded in 1905 and is headquartered in San Francisco, California.
VivoPower PLC
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Latest PCG
- PG&E downgraded by Truist with a new price target
- PG&E, Rewiring America and Google Launch First-of-its-Kind Virtual Power Plant to Help Lower Costs for All Customers
- PG&E Launches Strategic Review to Build a Better, More Affordable Energy Future for California Customers
- PG&E downgraded by BofA Securities with a new price target
- PG&E downgraded by Mizuho with a new price target
- PG&E downgraded by BMO Capital Markets with a new price target
- PG&E downgraded by Wells Fargo with a new price target
- Pacific Gas & Electric Co. filed SEC Form 8-K: Regulation FD Disclosure
- PG&E Statement on Senate Bill 492
- SEC Form 4 filed by EVP, Chief People Officer Vallejo Alejandro T
Latest VIVO
- SEC Form 6-K filed by VivoPower PLC
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Fully Retires US$28.8 Million Shareholder Debt Principal, Strengthening Balance Sheet Ahead of Nordic AI Infrastructure Buildout
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Secures US$50 Million PIPE At US$7.50 Conversion Price Per Share
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Appoints Group Finance Director
- SEC Form 6-K filed by VivoPower PLC